Vif
|
vif
|
HIV-1 Vif-mediated degradation of APOBEC3G requires CBFB |
PubMed
|
|
vif
|
HIV-1 Vif (N-terminal domain) interacts with CBFB in H9 cells |
PubMed
|
|
vif
|
HIV-1 Vif binds CBFB to inhibit RUNX1 transcriptional activator, which can be disrupted by mutating residue F68 in CBFB |
PubMed
|
|
vif
|
HIV-1 Vif is stabilized by CBFB |
PubMed
|
|
vif
|
HIV-1 Vif interacts with CBFB as demonstrated by co-immunoprecipitation assay |
PubMed
|
|
vif
|
HIV-1 Vif-mediated rescue of HIV-1 infectivity requires CBFB |
PubMed
|
|
vif
|
HIV-1 Vif interacts with CBFB in HEK293T and Jurkat T cells |
PubMed
|
|
vif
|
HIV-1 Vif, CBF-beta, CUL5, and ELOB/C form a complex that is required for Vif-mediated downregulation of A3G and A3F. CBF-beta regulates HIV-1 infectivity only in the presence of A3G |
PubMed
|
|
vif
|
Multiple lysine mutants in HIV-1 Vif, but not single lysine to arginine mutants, lack responsiveness to CBF-beta, indicating that more than one lysine in Vif mediates the ability of CBF-beta to stabilize Vif |
PubMed
|
|
vif
|
Amino-acid residues 125-141 at the C-terminal region of HIV-1 Vif are required for the Vif-CBF-beta interaction and the H108A, C114A, C133A, and H139A mutants show a decreased interaction with CBF-beta |
PubMed
|
|
vif
|
HIV-1 Vif residues 102 to 109 are critical for CBF-beta binding, and the remainder of the zinc finger (residues 100-140) strengthens the interaction |
PubMed
|
|
vif
|
An overall crystal structure indicates that the Vif-CBF-beta-CUL5-ELOB-ELOC complex has a U-shape architecture, including the two straight arms Vif-CBF-beta and CUL5 and the bent arm formation between ELOC and CUL5 and Vif interactions |
PubMed
|
|
vif
|
The loop 3 (amino acids 69-90) and helix 4 (amino acids 129-140) regions of CBF-beta and the N-terminal regions (amino acids 1-98) of HIV-1 Vif are important for the interaction between CBF-beta and Vif |
PubMed
|
|
vif
|
CBF-beta-mediated increase of HIV-1 Vif steady-state levels results in decreased cellular levels of all Vif-sensitive APOBEC proteins (A3C, A3D, A3F, A3G, and A3H haplotype II) |
PubMed
|
|
vif
|
Sucrose gradient centrifugation analysis demonstrates that CBF-beta disrupts the oligomerization status of HIV-1 Vif but not FIV Vif |
PubMed
|
|
vif
|
The solubility of HIV-1 Vif is significantly enhanced by co-expression of EloB, EloC, and CBF-beta in vitro |
PubMed
|
|
vif
|
The interaction of HIV-1 Vif with EloB/EloC complex is important for the binding of Vif to CBF-beta in cells. The Vif SOCS box mutant (SLQ to AAA) significantly disrupt its interaction with the EloB/EloC complex |
PubMed
|
|
vif
|
HIV-1 Vif can assemble into the Cul5-containing E3 ligase, the CUL5-RBX2-CBF-beta-ELOB-ELOC complex, in the presence of CBF-beta |
PubMed
|
|
vif
|
The HIV-1 Vif mutant G84A and 86SIEW/AAAA89 has a complete loss of the binding to CBF-beta, indicating that G84 and 86SIEW89 are critical for the Vif-CBF-beta interaction |
PubMed
|
|
vif
|
Simultaneous substitution of the three Vif-interacting residues L52, W53, and D55 and the two ELOC-interacting residues P41 and H48 in CUL5 impairs the ability of CUL5 to interact with the Vif-CBF-beta-ELOB-ELOC protein complex |
PubMed
|
|
vif
|
The N-terminal peptide (residues 6-12) of Vif forms an antiparallel beta-sheet with beta-strand S3 from CBF-beta. Vif residues W5, V7, and I9 point to the beta-barrel region and make hydrophobic contacts with their neighboring residues of CBF-beta |
PubMed
|
|
vif
|
The absence of Vif-CBF-beta reduces the interaction between the CUL5 and the EloC-EloB complex, indicating that the former two proteins have a critical role in promoting assembly of the pentameric complex |
PubMed
|
|
vif
|
HIV-1 Vif mutants W5S, W21S, W38S, W89S, F112S, and F115S have a reduced ability to interact with CBF-beta and these Vif hydrophobic residues are important for Vif-mediated degradation of A3F and A3G |
PubMed
|
|
vif
|
HIV-1 Vif residues 5 to 126 are required to form a stable complex with CBF-beta and Vif residues W5, W21, W38, W89, F112, and F115 contribute to hydrophobic interactions with CBF-beta |
PubMed
|
|
vif
|
HIV-1 Vif mutant E88A/W89A fails to bind to CBF-beta, which impairs Vif-mediated degradation of both A3F and A3G proteins and HIV-1 replication in non-permissive CEM cells |
PubMed
|
|
vif
|
CBF-beta enhances the rate of HIV-1 Vif biosynthesis at a posttranscriptional level |
PubMed
|
|
vif
|
CBFbeta1-126 is fully functional in the HIV-1 Vif-mediated degradation of A3G, but a further deletion of the C-terminal six amino acid residues (CBFbeta1-120) almost completely abolish its ability to contribute to Vif-induced A3G degradation |
PubMed
|
|
vif
|
The substitution of Leu64 or Ile66 with serine abolishes the ability of CBF-beta to interact with the Vif-EloB/EloC complex, while the substitution of Thr68 or Tyr69 with alanine has an intermediate effect on the interaction of CBF-beta with the complex |
PubMed
|
|
vif
|
CUL5/RBX2/ELOB/ELOC/Vif/CBF-beta complex catalyzes polyubiquitin chain formation on A3G in the presence of ubiquitin E2 UBE2R1 (CDC34) or UBCH5b (UBE2D2) |
PubMed
|
|
vif
|
HIV-1 Vif W21A and Vif W38A mutants have a reduced ability to interact with CBF-beta when compared to full-length Vif |
PubMed
|
|
vif
|
HIV-1 Vif induces ubiquitination of CBF-beta in cells |
PubMed
|
|
vif
|
The binding of HIV-1 Vif to CBF-beta is mutually exclusive of endogenous RUNX transcriptional factors in cells. Vif inhibits transcription of a RUNX1 reporter gene by competition with CBF-beta |
PubMed
|
|
vif
|
The interaction between the HIV-1 Vif PPLP motif (residues 161-164) and the 34-amino-acid C-terminal tail (residues 85-118) of EloB plays a role in promoting recruitment of CBF-beta to the Vif-Cul5 E3 complex |
PubMed
|
|
vif
|
UBE2F and RBX2 are required for activation of the polyubiquitin synthesis activity of Vif/CBF-beta/CUL5, leading to HIV-1 Vif-mediated degradation of A3G in cells |
PubMed
|
|
vif
|
The first six amino acids (residues 68-73) in loop 3 of CBFbeta are important for HIV-1 Vif binding and function |
PubMed
|
|
vif
|
The C-terminal tail (residues 131-182) of CBFbeta is dispensable for both Vif-induced A3G degradation and RUNX1-mediated gene transcription |
PubMed
|
|
vif
|
CBFbeta1-130, but not CBFbeta1-126, can fully support RUNX1-mediated gene transcription, indicating CBFbeta acts through different domains in its interaction with Vif and RUNX1 |
PubMed
|
|
vif
|
HIV-1 Vif coprecipitates with CBF-beta in HIV-1-infected H9 cells and transfected 293T cells |
PubMed
|
|
vif
|
CBF-beta and the N-terminal half of HIV-1 Vif enhance the affinity of Cul5 for Vif |
PubMed
|
|
vif
|
CBF-beta isoform 1 and isoform 2 stabilize HIV-1 Vif to degrade A3G and increase viral infectivity. CBF-beta stabilizes Vif proteins from multiple HIV-1 subtypes (A, B, C, D, AE, F, and G) |
PubMed
|
|
vif
|
CBF-beta isoform 1 and isoform 2 have a direct physical interaction with HIV-1 Vif and improves the solubility of Vif |
PubMed
|
|
vif
|
HIV-1 Vif is identified to have a physical interaction with core-binding factor, beta subunit (CBFB) in human HEK293 and Jurkat cell lines by using affinity tagging and purification mass spectrometry analyses |
PubMed
|
|
vif
|
A mutagenesis screen of CBF-beta surface residues reveals that a single amino acid change, F68D, disrupts HIV-1 Vif binding and its ability to degrade APOBEC3G |
PubMed
|
|
vif
|
Seven amino acid substitutions in CBF-beta result in either a significant reduction (Q8R, G61A, N63K, I102E, N104A, or E135R) or complete ablation (N104K) of the CBF-beta/RUNX1 interaction, which does not disrupt the interaction with HIV-1 Vif |
PubMed
|